Web5 jul. 2024 · IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. [Epub ahead of print] DOI:10.1016/S1470-2045 (19)30320-1 Clinicaltrials.gov (2024). WebSézary syndrome (SS), the most aggressive form of cutaneous T-cell lymphoma (CTCL), is characterized by a high expression of the KIR3DL2 receptor. Speaking f...
102 - NOS Teletekst - Nederlandse Omroep Stichting
WebNOS Teletekst 102 N O S B I N N E N L A N D Van Kooten reageert op dood De Bie. 112 Volkskrant-journalist geïntimideerd 105 Feyenoord schermt veld af met net.. 106 … Web1 nov. 2014 · IPH4102 antitumor activity was mediated by antibody-dependent cell cytotoxicity and phagocytosis. IPH4102 improved survival and reduced tumor growth in … immoscout24 spiez
IPH4102 Alone or in Combination With Chemotherapy in …
Web1 aug. 2024 · IPH4102 is a humanised, first-in-class, monoclonal antibody that is designed to deplete KIR3DL2-expressing cells via antibody-dependent cell cytotoxicity and phagocytosis.11 The drug has shown anti-tumour activity in mouse xenograft models and ex-vivo autologous assays using patient-derived natural killer cells and Sézary cells.11 … WebProvided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an anti-LAG-3 antibody, an anti-PD-1 antibody, and an immunotherapeutic agent. Web6 jun. 2024 · IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of CTCL, an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few therapeutic options at … immoscout24 mietwohnung baselland